Ningbo MedicalSystem Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 7.27%

Ningbo MedicalSystem Biotechnology Co Ltd (300439) has an Asset Resilience Ratio of 7.27% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Ningbo MedicalSystem Biotechnology Co Lt PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥265.90 Million

≈ $38.91 Million USD Cash + Short-term Investments

Total Assets

CN¥3.66 Billion

≈ $534.88 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Ningbo MedicalSystem Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See Ningbo MedicalSystem Biotechnology Co Lt balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Ningbo MedicalSystem Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Ningbo MedicalSystem Biotechnology Co Lt.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥265.90 Million	7.27%
Total Liquid Assets	CN¥265.90 Million	7.27%

Asset Resilience Insights

Limited Liquidity: Ningbo MedicalSystem Biotechnology Co Ltd maintains only 7.27% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Ningbo MedicalSystem Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Ningbo MedicalSystem Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fleury S.A. SA:FLRY3	Diagnostics & Research	16.06%
Wuhan Thalys Med Tech Co Ltd SHG:603716	Diagnostics & Research	0.12%
Spectral Med Inc TO:EDT	Diagnostics & Research	11.67%
Bcal Diagnostics Ltd AU:BDX	Diagnostics & Research	0.00%
Genetic Signatures Ltd AU:GSS	Diagnostics & Research	60.91%
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%

Annual Asset Resilience Ratio for Ningbo MedicalSystem Biotechnology Co Ltd (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Ningbo MedicalSystem Biotechnology Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	4.35%	CN¥161.08 Million ≈ $23.57 Million	CN¥3.71 Billion ≈ $542.17 Million	+4.18pp
2023-12-31	0.17%	CN¥6.00 Million ≈ $877.99K	CN¥3.49 Billion ≈ $510.58 Million	-2.06pp
2022-12-31	2.24%	CN¥80.17 Million ≈ $11.73 Million	CN¥3.58 Billion ≈ $524.40 Million	-0.57pp
2021-12-31	2.80%	CN¥100.70 Million ≈ $14.74 Million	CN¥3.59 Billion ≈ $525.80 Million	-2.87pp
2017-12-31	5.67%	CN¥242.70 Million ≈ $35.51 Million	CN¥4.28 Billion ≈ $626.09 Million	-4.27pp
2016-12-31	9.95%	CN¥340.00 Million ≈ $49.75 Million	CN¥3.42 Billion ≈ $500.20 Million	-10.10pp
2015-12-31	20.04%	CN¥290.00 Million ≈ $42.44 Million	CN¥1.45 Billion ≈ $211.71 Million	--

pp = percentage points

About Ningbo MedicalSystem Biotechnology Co Ltd

SHE:300439 China Diagnostics & Research

Market Cap

$470.71 Million

CN¥3.22 Billion CNY

Market Cap Rank

#12718 Global

#3762 in China

Share Price

CN¥8.37

Change (1 day)

-0.24%

52-Week Range

CN¥8.37 - CN¥11.87

All Time High

CN¥49.34